Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  DBV Technologies    DBV   FR0010417345

DBV TECHNOLOGIES (DBV)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
81.94(c) 82.06(c) 82.37(c) 80.2(c) 82.05(c) Last
113 902 41 881 54 601 66 543 80 307 Volume
+0.75% +0.15% +0.38% -2.63% +2.31% Change
More quotes
Financials (€)
Sales 2017 14,0 M
EBIT 2017 -141 M
Net income 2017 -141 M
Finance 2017 115 M
Yield 2017 -
Sales 2018 18,6 M
EBIT 2018 -181 M
Net income 2018 -188 M
Finance 2018 7,21 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 133x
EV / Sales2018 106x
Capitalization 1 978 M
More Financials
Company
DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products.The company focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient,... 
More about the company
Surperformance© ratings of DBV Technologies
Trading Rating : Investor Rating :
More Ratings
Latest news on DBV TECHNOLOGIES
10/20 DBV TECHNOLOGIES : Announces Topline Results of Phase III Clinical Trial in Pean..
10/13 DBV TECHNOLOGIES : Announces Completion of Blinded Period in REALISE Study of Vi..
10/12 DBV TECHNOLOGIES : Announces Completion of Blinded Period in REALISE Study of Vi..
09/01 DBV TECHNOLOGIES : to Attend Upcoming Investor Conferences
09/01 DBV TECHNOLOGIES : DBV Technologies to Attend Upcoming Investor Conferences
08/29 DBV TECHNOLOGIES : Announces Completion of Enrollment in Phase III Extension Stu..
08/29 DBV TECHNOLOGIES : Announces Completion of Enrollment in Phase III Extension Stu..
08/02 DBV TECHNOLOGIES : Initiates Phase III Study of Viaskin Peanut in Peanut-Allergi..
07/29 DBV TECHNOLOGIES : Reports First Half 2017 Financial Results
07/28 DBV TECHNOLOGIES : Reports First Half 2017 Financial Results
More news
Sector news : Diagnostic & Testing Substances Manufacturers
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Diagnostic & Testing Substances Manufacturers
Latest Tweets
10/21DBV Technologies Announces Topline Results of Phase III Clinical Trial in Pea.. 
10/21DBV Technologies Plunges By Half On Allergy Drug Trial's Failure  
10/20DBV Technologies peanut allergy drug fails key study
2
10/20DBV Technologies peanut allergy drug fails key study  
10/20DBV Technologies peanut allergy drug fails key study  
More tweets
Qtime:58
News from SeekingAlpha
10/20 After Hours Gainers / Losers
10/20 DBV Tech's Viaskin Peanut flunks pivotal study; shares down 59% after hours
10/17 EDITORS' PICKS DAILY : A Detailed Market Outlook, REITs & Buffett
10/17 AIMMUNE THERAPEUTICS AND DBV TECHNOL : 2 Different Approaches To Peanut Allergy ..
10/11 Q4 Biotech Catalyst Watchlist
Chart DBV TECHNOLOGIES
Duration : Period :
DBV Technologies Technical Analysis Chart | DBV | FR0010417345 | 4-Traders
Technical analysis trends DBV TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 102 €
Spread / Average Target 24%
EPS Revisions
Managers
NameTitle
Pierre-Henri Benhamou Chairman & Chief Executive Officer
David S. Schilansky Chief Operating & Financial Officer
Bertrand Dupont Chief Technology Officer
Lucia Septién Chief Medical Officer
Hugh A. Sampson Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
DBV TECHNOLOGIES20.87%2 330
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223